Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1/2 trial.

Ruhnke L, Schliemann C, Mikesch JH, Stelljes M, Fransecky L, Steffen B, Kaufmann M, Burchert A, Rank A, Hanoun M, Höllein A, Kraus S, Schäfer-Eckart K, Hänel M, Haake A, Fiebig F, Kramer M, Zukunft S, Kunadt D, Middeke JM, Sockel K, Schetelig J, Platzbecker U, von Bonin M, Röhnert MA, Oelschlägel U, Wagenführ L, Thiede C, Herold S, Poitz D, Stölzel F, Baldus CD, Serve H, Wermke M, Bornhäuser M, Röllig C.

Open source

DOI: 10.1016/s2352-3026(25)00358-8
Published: 2026-03-01
Container: Lancet Haematol
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s2352-3026-25-00358-8,
  title = {Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1/2 trial.},
  author = {Ruhnke L and  Schliemann C and  Mikesch JH and  Stelljes M and  Fransecky L and  Steffen B and  Kaufmann M and  Burchert A and  Rank A and  Hanoun M and  Höllein A and  Kraus S and  Schäfer-Eckart K and  Hänel M and  Haake A and  Fiebig F and  Kramer M and  Zukunft S and  Kunadt D and  Middeke JM and  Sockel K and  Schetelig J and  Platzbecker U and  von Bonin M and  Röhnert MA and  Oelschlägel U and  Wagenführ L and  Thiede C and  Herold S and  Poitz D and  Stölzel F and  Baldus CD and  Serve H and  Wermke M and  Bornhäuser M and  Röllig C.},
  year = {2026},
  journal = {Lancet Haematol},
  doi = {10.1016/s2352-3026(25)00358-8},
  url = {https://doi.org/10.1016/s2352-3026(25)00358-8}
}

RIS

TY  - JOUR
TI  - Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1/2 trial.
AU  - Ruhnke L
AU  -  Schliemann C
AU  -  Mikesch JH
AU  -  Stelljes M
AU  -  Fransecky L
AU  -  Steffen B
AU  -  Kaufmann M
AU  -  Burchert A
AU  -  Rank A
AU  -  Hanoun M
AU  -  Höllein A
AU  -  Kraus S
AU  -  Schäfer-Eckart K
AU  -  Hänel M
AU  -  Haake A
AU  -  Fiebig F
AU  -  Kramer M
AU  -  Zukunft S
AU  -  Kunadt D
AU  -  Middeke JM
AU  -  Sockel K
AU  -  Schetelig J
AU  -  Platzbecker U
AU  -  von Bonin M
AU  -  Röhnert MA
AU  -  Oelschlägel U
AU  -  Wagenführ L
AU  -  Thiede C
AU  -  Herold S
AU  -  Poitz D
AU  -  Stölzel F
AU  -  Baldus CD
AU  -  Serve H
AU  -  Wermke M
AU  -  Bornhäuser M
AU  -  Röllig C.
PY  - 2026
JO  - Lancet Haematol
DO  - 10.1016/s2352-3026(25)00358-8
UR  - https://doi.org/10.1016/s2352-3026(25)00358-8
ER  -

APA

L, R., C, S., JH, M., M, S., L, F., B, S., M, K., A, B., A, R., M, H., A, H., S, K., K, S., M, H., A, H., F, F., M, K., S, Z., D, K., JM, M., K, S., J, S., U, P., M, V. B., MA, R., U, O., L, W., C, T., S, H., D, P., F, S., CD, B., H, S., M, W., M, B., & C., R. (2026). Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1/2 trial.. Lancet Haematol. https://doi.org/10.1016/s2352-3026(25)00358-8

Source records

europe-pmc · retrieved 2026-09-27T06:00:38.154Z